On January 11, Jining Municipal People's Government held a press conference to interpret the Policies and Measures on Supporting the High-quality Development of Jining's Biomedical Industry, aiming to be a pioneer in medicine R&D and high-end preparation industry in Jining National High-Tech Industrial Development Zone and promote the high-quality development of Jining's pharmaceutical industry.

Consisting of eight parts and 18 policy measures, the Policies and Measures provides support for the industrialization of innovative medicines, development of traditional Chinese medicine, industrialization of innovative medical equipment, development of formula food for special medical use, industrialization of innovative veterinary drugs, expansion of Chinese and international markets, construction of pharmaceutical innovation service platforms, and subcontract production of innovative medicines and medical equipment.

Subsidies of up to 30 million yuan, 15 million yuan, and 5 million yuan will be given to Class 1 innovative medicines, Class 2 improved new medicines, and first generic medicines respectively. Subsidies of 3 million yuan and 2 million yuan will be given to Class III and Class II medical devices registered in accordance with the innovation and priority procedures respectively. Subsidies of 1 million yuan and 500,000 yuan will be given to the varieties included in the national and provincial centralized procurement and the national medical insurance drug catalog for the first time, respectively. For pharmaceutical R&D and clinical trial bases built in Jining, a subsidy of 5% of the total actual investment in fixed assets will be granted, with a maximum amount of 10 million yuan.